What is the most appropriate valuation methodology for a company with significant intangible assets but no current revenue, such as a biotech startup in the pre-clinical stage?
An advanced Valuation question — expect it in final rounds and case-heavy interviews (IB, PE, Big-4 Transaction Services).
THE SHORT ANSWER
For a pre-revenue biotech, DCF is unreliable due to uncertain cash flows, and comps are difficult because few public peers have no revenue. The most appropriate method is a risk-adjusted NPV (rNPV) of the drug pipeline, discounting expected cash flows from each drug candidate by the probability of approval. Alternatively, a sum-of-the-parts using comparable transactions for similar stage assets can work. DCF or comps alone would be inappropriate.
WHAT INTERVIEWERS LISTEN FOR
- ✓Pre-revenue, intangible-heavy company
- ✓DCF and comps are unreliable
- ✓Use risk-adjusted NPV (rNPV)
- ✓Consider comparable transactions
COMMON MISTAKES
- ✗Using standard DCF without probability adjustment
- ✗Using P/E or EV/EBITDA multiples
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you value a company with no revenue?
- Explain accretion/dilution analysis.
- How would you value a company in a cyclical industry?
- When calculating WACC for a company with multiple divisions in different countries, what is the correct approach?
- How does a private equity buyer use an LBO to set the maximum price it can pay, and why is this a valuation floor?
- How do net operating loss carryforwards (NOLs) enter a valuation, and why don't you just deduct them like net debt?